Banner - Collaborative Care Symposium
News
All NewsContributorsMoney Matters
Media
All VideosExpert InterviewsMedical World NewsPodcastsBeyond The WallsCase Based Roundtable SeriesCase of the QuarterEyeViewGrand RoundsInsightsRapid ReadoutSpecial ReportViewpointsWhat’s Your WhEYE?
Conferences
Conference CoverageConference Listing
Events
More
Publications
Digital EditionEurope Ophthalmology TimesModern RetinaSupplements and Featured Publications
CME
Partners
Resources
Job BoardSponsored

Subscribe

  • News
  • Media
  • Conferences
  • Events
  • Publications
  • CME
  • Partners
  • Subscribe
  • Resources
  • AMD
  • Biosimilars
  • COVID-19
  • Cataract
    • Cataract Surgery
  • Cataract Therapeutics
  • Clinical Diagnosis
    • The Residency Report
    • iOpeners
    • NeuroOp Guru
  • Cornea
  • DME
  • Dry Eye
    • Dry Eye Awareness
  • Gene Therapy
  • Geographic Atrophy
  • IOL
    • IOL Advances
  • Imaging
  • Interventional Glaucoma
    • Glaucoma Awareness
    • Glaucoma Insights
    • Therapeutic Glaucoma
  • OCT
  • Ocular Allergy
  • Ocular Surface Disease
  • Optic Relief
  • Optometry
  • Pediatrics
  • Pharmacy
  • Practice Management
    • Indispensable
  • Presbyopia
  • Ptosis
  • Refractive
    • Refractive Surgery
  • Retina
  • Surgery
  • Technology
  • Therapeutics
  • Understanding Antibiotic Resistance
  • Workplace
Spotlight -
Retina
Advertisement

Gerald J. Roper, MD

Advertisement

Articles by Gerald J. Roper, MD

Cataract eye surgery

Protecting cataract patients and their surgeons' practices

ByGerald J. Roper, MD
June 29th 2020

Maximizing refractive surgery is key to ensuring prosperous future

Advertisement

Latest Updated Articles



    Advertisement
    Advertisement

    Trending on Ophthalmology Times - Clinical Insights for Eye Specialists

    1

    Iolyx Therapeutics and Laboratoires Théa enter into agreement over ILYX-002 for the treatment of OSD

    2

    Avisi Technologies treats first patient in SAPPHIRE trial for glaucoma

    3

    PainReform launches development plan for OcuRing-K, readies phase 2 trial

    4

    Phase 1 trial findings confirm safety and tolerability of Huons’ dry eye therapy

    5

    FDA approves Amneal Pharmaceuticals' cyclosporine ophthalmic emulsion 0.05%

    • About
    • Advertise
    • Privacy
    • Editorial Info
    • Editorial Board
    • Terms and Conditions
    • Contact Us
    • Do Not Sell My Personal Information
    • Job Board
    Contact Info

    259 Prospect Plains Rd, Bldg H
    Cranbury, NJ 08512

    609-716-7777

    • Ophthalmology Times
    • Modern Retina
    • Optometry Times
    • Ophthalmology Times Europe
    EyeCare Network
    Brand Logo

    © 2025 MJH Life Sciences®

    All rights reserved.

    Home
    About Us
    News
    Contact Us